Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Adult heart tumor refers to neoplasms of the heart that manifest in adults and generally present with a variety of non-specific manifestations (depending on tumor site and infiltration) such as weight loss, exhaustion, hemorrhagic pericardial effusion, heart failure, arrhythmias, and embolisms, or that can also be asymptomatic. In adults 75% of heart tumors are benign, with myxoma being the most common benign tumor (accounting for 50-70% of all primary heart tumors) and rhabdomyosarcoma comprising 75% of malignant heart tumors. Other malignant tumors of the heart include fibrosarcoma and leiomyosarcoma (see these terms).
Biomarker and diagnostic research for primary adult heart tumor has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for primary adult heart tumor.
330 publications have been identified in PubMed for primary adult heart tumor. Kisho has analyzed 71 by research type. Research spans Epidemiology / Natural History (34%), Clinical Trial Publication (31%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 24 | 34% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 9:17 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Clinical study results |
22 |
31% |
Research summaries | 9 | 13% |
Patient case studies | 8 | 11% |
Laboratory research | 6 | 8% |
Testing and diagnosis research | 2 | 3% |
Masson Regnault M (2026). [PMID: 41469898](https://pubmed.ncbi.nlm.nih.gov/41469898/). *J Eur Acad Dermatol Venereol*. [Review / Meta-Analysis]
Aizpuru M (2026). [PMID: 40639783](https://pubmed.ncbi.nlm.nih.gov/40639783/). *Ann Thorac Surg*. [Epidemiology / Natural History]
Sawma T (2026). [PMID: 40751721](https://pubmed.ncbi.nlm.nih.gov/40751721/). *Mayo Clin Proc*. [Epidemiology / Natural History]
Carpino G (2026). [PMID: 40513068](https://pubmed.ncbi.nlm.nih.gov/40513068/). *Hepatology*. [Case Report / Case Series]
Anker MS (2026). [PMID: 40884070](https://pubmed.ncbi.nlm.nih.gov/40884070/). *Eur Heart J*. [Clinical Trial Publication]
Salem JE (2026). [PMID: 40884033](https://pubmed.ncbi.nlm.nih.gov/40884033/). *Eur Heart J*. [Epidemiology / Natural History]
Curman P (2026). [PMID: 41722760](https://pubmed.ncbi.nlm.nih.gov/41722760/). *Int J Infect Dis*. [Epidemiology / Natural History]
van den Berg PF (2026). [PMID: 41014601](https://pubmed.ncbi.nlm.nih.gov/41014601/). *Eur J Prev Cardiol*. [Diagnostic / Biomarker]
Ciardiello D (2026). [PMID: 41443411](https://pubmed.ncbi.nlm.nih.gov/41443411/). *Ann Oncol*. [Clinical Trial Publication]
Shyr D (2026). [PMID: 41505144](https://pubmed.ncbi.nlm.nih.gov/41505144/). *JAMA Oncol*. [Epidemiology / Natural History]